Coordinatore | MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
Nazionalità Coordinatore | Austria [AT] |
Sito del progetto | http://www.tolerage.eu/ |
Totale costo | 10˙136˙875 € |
EC contributo | 7˙736˙931 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2007-A |
Funding Scheme | CP-IP |
Anno di inizio | 2008 |
Periodo (anno-mese-giorno) | 2008-04-01 - 2012-09-30 |
# | ||||
---|---|---|---|---|
1 |
MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
AT (INNSBRUCK) | coordinator | 0.00 |
2 |
CENTER OF EXCELLENCE IN MEDICINE AND IT GMBH
Organization address
address: KARL KAPFERER STRASSE 5 contact info |
AT (INNSBRUCK) | participant | 0.00 |
3 |
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Organization address
address: Im Neuenheimer Feld 280 contact info |
DE (HEIDELBERG) | participant | 0.00 |
4 |
FONDAZIONE HUMANITAS PER LA RICERCA
Organization address
address: Via Manzoni 56 contact info |
IT (ROZZANO) | participant | 0.00 |
5 |
GENOPOLIS CONSORZIO DI GENOMICA FUNZIONALE
Organization address
address: PIAZZA DELLA SCIENZA 2 UNIVERSITA DEGLI STUDI MILANO contact info |
IT (MILAN) | participant | 0.00 |
6 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 0.00 |
7 |
KANTONSSPITAL ST. GALLEN
Organization address
address: Rorschacherstrasse 95 contact info |
CH (ST. GALLEN) | participant | 0.00 |
8 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 0.00 |
9 |
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
Organization address
address: PIAZZA DELL'ATENEO NUOVO 1 contact info |
IT (MILANO) | participant | 0.00 |
10 |
UNIVERSITEIT UTRECHT
Organization address
address: Heidelberglaan 8 contact info |
NL (UTRECHT) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'When restoration of the immune response in older age is the target of basic and clinical research, boosting innate and adaptive immunity, e.g. by more efficient vaccination strategies, is the general approach. However, TOLERAGE has a fundamentally different focus, i.e. restoring the age-dependent decline of auto-tolerance that underlies the development of the paradigmatic age-associated diseases atherosclerosis (AS) and rheumatoid arthritis (RA). These diseases represent the major medical and socioeconomic burden in aging societies. They start earlier in life but become clinically manifest with increasing age. To reach this aim a consortium of ten partner groups was formed that have an outstanding track record in areas of immunology pertinent for this task. The work of TOLERAGE will focus on three major issues, viz. 1. Investigating basic principles of the induction of central and peripheral tolerance in mice against autoantigens, including heat shock protein 60 (HSP60) that has been shown to play a major role in the development of AS and RA. 2. Determination of the mediators of central and peripheral tolerance that are responsible for the T effector/T regulatory cell dysbalance in older age in general and in AS and RA in particular. 3. Translation of the results obtained in (a) and (b) into practical application for the prevention and treatment of AS and RA by appropriate vaccines. For all partners, important technical platforms will be available, including unique transgenic and knockout mouse strains, sophisticated models for in vitro and in vivo transfection of dendritic cells (DCs) and a well established Functional Genomics Facility.'
A Nanoscale Artificial Nose to easily detect Volatile Biomarkers at Early stages of Lung Cancer and Related Genetic Mutations
Read MoreSmall Molecule Inhibitors of the Trimeric Influenza Virus Polymerase Complex
Read MorePhase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector
Read More